Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

29.06.2026

1 AJR Am J Roentgenol
2 Am J Clin Oncol
4 Ann Oncol
4 Ann Surg Oncol
12 BMC Cancer
1 Br J Cancer
8 Breast Cancer
1 Breast Cancer (Dove Med Press)
10 Breast Cancer Res
12 Breast Cancer Res Treat
3 Breast J
1 Cancer
2 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
1 Clin Breast Cancer
1 Curr Treat Options Oncol
3 Eur J Surg Oncol
6 Eur Radiol
1 Int J Cancer
1 Int J Oncol
5 Int J Radiat Oncol Biol Phys
2 J Natl Cancer Inst
1 J Nucl Med
1 Mol Ther Oncol
7 NPJ Breast Cancer
3 PLoS One
1 Proc Natl Acad Sci U S A
1 Radiol Artif Intell
2 Radiology


    AJR Am J Roentgenol

  1. ROSENKRANTZ AB
    June 2026: Artificial Intelligence (AI) for Future Breast Cancer Prediction, AI for Fracture Detection, CEUS for O-RADS Ultrasound, and More.
    AJR Am J Roentgenol. 2026 Jun 24:1-2. doi: 10.2214/AJR.25.33518.
    >> Share


    Am J Clin Oncol

  2. MENDES SILVA A, Lopes de Almeida Rizzi SK, Baptista Rodrigues F, Estevao A, et al
    Upper Extremity Lymphedema???: Performance of a Risk Prediction Model in Women Undergoing Surgery for Breast Cancer.
    Am J Clin Oncol. 2026 Jun 15. doi: 10.1097/COC.0000000000001339.
    >> Share

  3. KASLIWAL N, Gordon M, Becker E, Ding K, et al
    Emergence of Single-Week Adjuvant Radiation Therapy for Early-Stage Breast Cancer in the United States.
    Am J Clin Oncol. 2026 May 25. doi: 10.1097/COC.0000000000001336.
    >> Share


    Ann Oncol

  4. GLUZ O, Nitz U, Christgen M, Kuemmel S, et al
    Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).
    Ann Oncol. 2026;37:920-935.
    >> Share

  5. GARRIDO-CASTRO AC, Kim SE, Li T, Desrosiers J, et al
    SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
    Ann Oncol. 2026 Jun 20:S0923-7534(26)00960-9. doi: 10.1016/j.annonc.2026.
    >> Share

  6. GARRIDO-CASTRO AC
    TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?
    Ann Oncol. 2026 Jun 25:S0923-7534(26)00967-1. doi: 10.1016/j.annonc.2026.
    >> Share

  7. GIRIDHAR KV, Goetz MP
    Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.
    Ann Oncol. 2026;37:873-876.
    >> Share


    Ann Surg Oncol

  8. CHAN K, Cohen L, Cotler JH, Carthcart-Rake E, et al
    Breast Cancer Outcomes in Intersex Individuals in the National Cancer Database.
    Ann Surg Oncol. 2026 Jun 20. doi: 10.1245/s10434-026-20027.
    >> Share

  9. LAUDE E, Guyon C, Diaz LM, Cabel L, et al
    Association Between Axillary Surgical Management and Survival for Patients With De Novo Metastatic Breast Cancer.
    Ann Surg Oncol. 2026 Jun 23. doi: 10.1245/s10434-026-19992.
    >> Share

  10. UEKI Y, Horimoto Y, Yuan M, Wu R, et al
    Cyclin E1 Expression Predicts Poorer Outcome in HER2-positive Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2026 Jun 27. doi: 10.1245/s10434-026-20021.
    >> Share

  11. RADEMACHER N, Gutnik LA, Broman KK
    Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2026 Jun 26. doi: 10.1245/s10434-026-19968.
    >> Share


    BMC Cancer

  12. ATCI MM, Erciyestepe M, Erturk K
    Efficacy and tolerability of CDK 4/6 inhibitors in HR-positive HER2-negative de novo metastatic breast cancer patients aged >/= 70 years.
    BMC Cancer. 2026 Jun 25. doi: 10.1186/s12885-026-16430.
    >> Share

  13. SOWERBY C, Lemu K, Landsteiner A, Ullman K, et al
    Comparative efficacy and harms of adjuvant whole breast hypofractionation or external beam accelerated partial breast irradiation for treatment of breast cancer: a systematic review.
    BMC Cancer. 2026 Jun 25. doi: 10.1186/s12885-026-16129.
    >> Share

  14. ANTONIO DNM, Annani-Akollor M, Fondjo LA, Anang-Quartey Y, et al
    Over-presentation of apolipoprotein E gene variants E3/E4 and cardiovascular disease risk factors among Ghanaian breast cancer patients.
    BMC Cancer. 2026 Jun 23. doi: 10.1186/s12885-026-16354.
    >> Share

  15. MO D, Li C, Mao X, Zheng L, et al
    The clinical value of the combined detection of circulating low rectangle density neutrophils and inflammatory markers in breast cancer with lymph node metastasis.
    BMC Cancer. 2026 Jun 23. doi: 10.1186/s12885-026-16384.
    >> Share

  16. GETNET E, Adane G, Awoke Shiferaw E, Ayelegn Nibret T, et al
    Evaluation of tumor-infiltrating lymphocytes across breast cancer stages at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
    BMC Cancer. 2026 Jun 22. doi: 10.1186/s12885-026-16359.
    >> Share

  17. KARSONO R, Al Azhar M, Utari AD, Perdana AB, et al
    PD-L1 copy number loss is associated with lower survival in women with advanced breast cancer in Indonesian cohort.
    BMC Cancer. 2026 Jun 19. doi: 10.1186/s12885-026-16328.
    >> Share

  18. DA COSTA NC, Fernandes ACP, Damin APS
    Prognostic relevance of increased tumor-infiltrating lymphocytes in residual TNBC following neoadjuvant chemotherapy.
    BMC Cancer. 2025;25:1856.
    >> Share

  19. GOERG A, Piendl G, Albert V, Ortmann O, et al
    Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition.
    BMC Cancer. 2025;25:978.
    >> Share

  20. FATHIMA ZS, Suresh TNR, Kattepur AK
    Immunohistochemical expression of tumor-infiltrating lymphocytes CD8 and FOXP3 in invasive ductal carcinoma of breast.
    BMC Cancer. 2025;25:1550.
    >> Share

  21. SENDUR MAN, Hizal M, Cakar B, Aktepe OH, et al
    Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program.
    BMC Cancer. 2025 Nov 22. doi: 10.1186/s12885-025-15287.
    >> Share

  22. LYU Q, Yuan H, Lin Z, Barcus R, et al
    A large scale multi-dataset investigation of brain metastases distribution based on primary cancer type.
    BMC Cancer. 2025;25:1821.
    >> Share

  23. GERSHFELD-LITVIN A, Shay-Peretz N, Hanalis-Miller T
    Motherhood with HBOC in Israel: experiencing preventive disruption.
    BMC Cancer. 2025;25:1928.
    >> Share


    Br J Cancer

  24. METCALFE K, Narod SA, Poll A, Hoey C, et al
    Frequency of germline pathogenic variants in breast cancer predisposing genes in a national cohort of young women with breast cancer.
    Br J Cancer. 2026 Jun 23. doi: 10.1038/s41416-026-03502.
    >> Share


    Breast Cancer

  25. YAMANAKA T, Sohn J, Sudo K, Mukai H, et al
    Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.
    Breast Cancer. 2026 Jun 24. doi: 10.1007/s12282-026-01865.
    >> Share

  26. OSHI M, Nakayama T, Ota I, Sasamoto M, et al
    Multidimensional impact of fixed-dose subcutaneous trastuzumab-pertuzumab on oncology workflow and patient time burden in a real-world study.
    Breast Cancer. 2026;33:288-296.
    >> Share

  27. TSURU T, Watanabe T, Kouzu K, Yamagishi Y, et al
    A simple morphometric algorithm based on nuclear atypia features of invasive breast carcinoma: relationship with nuclear grade, Ki-67 level, and hormone receptor status.
    Breast Cancer. 2026;33:905-918.
    >> Share

  28. MURATA T, Kumamaru H, Yoshida M, Kinukawa N, et al
    Prognostic impact of progesterone receptor status in patients with breast cancer and isolated locoregional recurrence.
    Breast Cancer. 2026 Jun 21. doi: 10.1007/s12282-026-01882.
    >> Share

  29. LEE TH, Cho WK, Lee H, Kim TG, et al
    Prognostic impact of radiotherapy dose to the axilla in cN + /ypN0 breast cancer after primary systemic therapy and sentinel lymph node biopsy: toward true de-escalation of axillary management.
    Breast Cancer. 2026 Jun 24. doi: 10.1007/s12282-026-01879.
    >> Share

  30. MITSUEDA R, Ohi Y, Mochitomi Y, Takaki R, et al
    Postoperative course and safety profile of the suture scaffold technique in breast-conserving surgery: a single-institution observational study.
    Breast Cancer. 2026;33:359-367.
    >> Share

  31. HORIMOTO Y, Semba R, Ushigusa T, Kusama H, et al
    Limits of substitution and context-dependent selective omission of Oncotype DX recurrence score testing.
    Breast Cancer. 2026;33:820-828.
    >> Share

  32. INOUE K, Kawasaki A, Sasaki T, Doi T, et al
    A novel quantification method for automatic computation of breast density from mammography images using deep learning.
    Breast Cancer. 2026;33:324-332.
    >> Share


    Breast Cancer (Dove Med Press)

  33. CHARAN M, Jones TH, Ahirwar DK, Acharya N, et al
    Induced Electric Fields Inhibit Breast Cancer Growth and Metastasis and Modulate the Immune Tumor Microenvironment.
    Breast Cancer (Dove Med Press). 2026;18:604098.
    >> Share


    Breast Cancer Res

  34. TELANG S, Clem BF, Miret AAH, Price L, et al
    Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancer.
    Breast Cancer Res. 2026 Jun 25. doi: 10.1186/s13058-026-02336.
    >> Share

  35. WANG J, Yao L, Chen Y, Zhu Q, et al
    FBXO5 regulates RPL23A to promote MDM2-mediated p53 degradation and facilitate malignant progression of breast cancer.
    Breast Cancer Res. 2026 Jun 25. doi: 10.1186/s13058-026-02335.
    >> Share

  36. PENA-ENRIQUEZ R, Guerrero-Zotano A, Bermejo B, Diaz-Chacon A, et al
    Breastfeeding shapes a unique tumor-immune landscape in pregnancy-associated breast cancer from GEICAM-EMBARCAM study.
    Breast Cancer Res. 2026 Jun 24. doi: 10.1186/s13058-026-02330.
    >> Share

  37. NACER DF, Veerla S, Sasiain I, Hakkinen J, et al
    Comprehensive comparison of homologous recombination deficiency predictors in early-stage triple-negative breast cancer.
    Breast Cancer Res. 2026;28:115.
    >> Share

  38. ZAREAN E, Li S, Makalic E, Milne RL, et al
    Tumour-based DNA methylation markers of breast cancer survival: a pooled analysis of 2157 cases.
    Breast Cancer Res. 2026 Jun 26. doi: 10.1186/s13058-026-02327.
    >> Share

  39. KANG E, Shin IB, Jung JJ, Byeon J, et al
    Differential prognostic significance of tumor size and node in invasive lobular carcinoma of breast.
    Breast Cancer Res. 2025;27:194.
    >> Share

  40. SARCINELLA A, Kholia S, Femmino S, Cedrino M, et al
    IL-3/STAT5/miR-155-5p axis supports stem-related pathway reprogramming in TNBC.
    Breast Cancer Res. 2025;27:195.
    >> Share

  41. SASAKI A, Hosonuma M, Maruyama Y, Funayama E, et al
    Cetirizine suppresses cancer-associated fibroblast-mediated fibrotic remodeling and epithelial-mesenchymal transition via histamine H(1) receptor inverse agonism.
    Breast Cancer Res. 2026;28:113.
    >> Share

  42. GORDON B, Swaminathan B, Youn SW, Obacz NA, et al
    Tumor cell Jagged-1 promotes regional lymphatic metastasis and predicts recurrence in node-positive breast cancer.
    Breast Cancer Res. 2026 Jun 19. doi: 10.1186/s13058-026-02331.
    >> Share

  43. STABELLINI N, de Oliveira SD, Mizukami T, Sweeney SM, et al
    Impact of somatic PIK3CA mutations on clinical outcomes in HER2-positive breast cancer.
    Breast Cancer Res. 2026 Jun 20. doi: 10.1186/s13058-026-02324.
    >> Share


    Breast Cancer Res Treat

  44. JAYASWAL RP, Rana AK, Badyal RK
    Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.
    Breast Cancer Res Treat. 2026;217:65.
    >> Share

  45. JAYASWAL RP, Thapliyal S, Badyal RK
    Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy.
    Breast Cancer Res Treat. 2026;217:64.
    >> Share

  46. VASIGH M, Ruth K, Bleicher RJ, Lyons W, et al
    Impact of axillary surgery on survival in de novo metastatic breast cancer with primary tumor resection.
    Breast Cancer Res Treat. 2026;217:56.
    >> Share

  47. LEONARD LD, Cohen E, Perry R, Sun J, et al
    Surgeon interpretation of margin status utilizing intraoperative 3D tomosynthesis during breast-conserving surgery.
    Breast Cancer Res Treat. 2026;217:58.
    >> Share

  48. YAMAGUCHI Y, Hoshino M, Shimoi T, Tamura H, et al
    Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer.
    Breast Cancer Res Treat. 2026;217:59.
    >> Share

  49. ETAN T, Cohen L, Bar Y, Leshem Y, et al
    Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations.
    Breast Cancer Res Treat. 2026;217:54.
    >> Share

  50. ZHENG S, Sullivan P, Vadehra K, Kim J, et al
    Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer.
    Breast Cancer Res Treat. 2026;217:57.
    >> Share

  51. DABOUR MS, Shaaban A, Duprez DA, Zordoky BN, et al
    Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?
    Breast Cancer Res Treat. 2026;217:55.
    >> Share

  52. PLOTKE RL, Kanaya MR, Popok PJ, Webster SN, et al
    Subjective socioeconomic status moderates the relationship between objective neighborhood disadvantage and quality of life in middle- and older-aged women with breast cancer.
    Breast Cancer Res Treat. 2026;217:61.
    >> Share

  53. AHMED S, Mannala S, Mondal P, Mahmood W, et al
    Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.
    Breast Cancer Res Treat. 2026;217:62.
    >> Share

  54. ALBERT R, Thomas J, Sadeghi N, Reddy SM, et al
    Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen.
    Breast Cancer Res Treat. 2026;217:60.
    >> Share

  55. AKALIN C, Zaim G, Demir M
    Discrimination, spectrum, and clinical utility: ICG lymphography drainage time in axillary staging.
    Breast Cancer Res Treat. 2026;217:63.
    >> Share


    Breast J

  56. YU D, Zhu C, Yang S, Wang D, et al
    Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis.
    Breast J. 2026;2026:e5088737.
    >> Share

  57. IYENGAR AR, Downs EP, Mehta S, Rangarajan N, et al
    HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0.
    Breast J. 2026;2026:e7212120.
    >> Share

  58. BABAEE E, Soheyli M, Nafissi N
    Long-Term Side Effects of Breast Cancer Treatments: A Systematic Review.
    Breast J. 2026;2026:e6873605.
    >> Share


    Cancer


  59. Correction to "Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025".
    Cancer. 2026;132:e70507.
    >> Share


    Cancer Chemother Pharmacol

  60. PASUPULATI SL, Srinivasa Rao K, Sharma S, Madhavrao C, et al
    Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review.
    Cancer Chemother Pharmacol. 2025;95:87.
    >> Share

  61. ZHANG P, Zhang Y, Xue Z, Liu D, et al
    Risk factors and prediction models for cardiotoxicity induced by anthracyclines in malignant chemotherapy.
    Cancer Chemother Pharmacol. 2025;95:73.
    >> Share


    Cancer Epidemiol Biomarkers Prev

  62. ZHANG LQ, Xia W, Yu G, Saravanan R, et al
    Development of the cf-MMSP assay for enhanced analytical sensitivity of methylated DNA in breast cancer liquid biopsy.
    Cancer Epidemiol Biomarkers Prev. 2026.
    >> Share


    Cancer Lett

  63. ZHAO H, Tian H, Nuerbieke T, Ma K, et al
    Immunotherapy Resistance in Triple-Negative Breast Cancer: Mechanisms and Emerging Therapeutic Strategies.
    Cancer Lett. 2026 Jun 20:218690. doi: 10.1016/j.canlet.2026.218690.
    >> Share


    Clin Breast Cancer

  64. MAGANINHO B, Peleteiro B, Pereira R, Fougo JL, et al
    The Clinical Impact of Not Performing Axillary Lymph Node Dissection in pN+sn Breast Cancer Patients Undergoing Total Mastectomy.
    Clin Breast Cancer. 2026;26:56-63.
    >> Share


    Curr Treat Options Oncol

  65. MARTINEZ-LOPEZ S, Blasco-Navarro C, Blas-Gomez S, Bravo I, et al
    Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.
    Curr Treat Options Oncol. 2026;27:33.
    >> Share


    Eur J Surg Oncol

  66. PALSHOF FK, Korsholm RHR, Duriaud HM, Grell K, et al
    The impact of drains on postoperative seroma and infection after mastectomy: A retrospective study in Danish women with breast cancer.
    Eur J Surg Oncol. 2026;52:111970.
    >> Share

  67. MORGAN JL, Hubbard T, Herbert E, Hartup S, et al
    National United Kingdom study of the management of breast cancer locoregional recurrence (MARECA) study: Analysis of disease presentation and patient management.
    Eur J Surg Oncol. 2026;52:111881.
    >> Share

  68. COOKE R, Baxter P, Wyld L, Morgan J, et al
    Factors influencing women's preferences and decision making regarding the extent of axillary surgery in breast cancer: A systematic review.
    Eur J Surg Oncol. 2026;52:111923.
    >> Share


    Eur Radiol

  69. ZHANG T, Rasoolzadeh N, Mann RM
    Can multimodal AI bridge imaging and prognosis in breast cancer?
    Eur Radiol. 2026;36:5592-5594.
    >> Share

  70. PESAPANE F, Depretto C, Rotili A, Penco S, et al
    Should AI results be disclosed in mammography reports? A randomised survey study of patient responses to concordant and discordant interpretations.
    Eur Radiol. 2026;36:5645-5655.
    >> Share

  71. MARZIALI S, Corradini L, Depretto C, Della Pepa G, et al
    Assessing breast MRI image quality: the bMRI-QUAL scoring system.
    Eur Radiol. 2026;36:5669-5677.
    >> Share

  72. ONAR MA, Jabbarli E, Polat AV, Demirag G, et al
    Breast edema score as a biomarker of tumor aggressiveness and its predictive value for neoadjuvant chemotherapy response.
    Eur Radiol. 2026;36:5658-5668.
    >> Share

  73. LORENZON M, Minichetti P, Casotto L, Cereser L, et al
    Contrast-enhanced mammography versus breast MRI in the preoperative evaluation of the nipple-areola complex: data from a real-world setting.
    Eur Radiol. 2026;36:5630-5644.
    >> Share

  74. ROSSINI G, Lockey K, Rokoszak M, Pasculli M, et al
    Energy consumption of standard and contrast-enhanced mammography: a step towards sustainable breast imaging.
    Eur Radiol. 2026;36:5607-5615.
    >> Share


    Int J Cancer

  75. CHOKUNONGA E, Chirenje ZM, Borok M, Makunike-Mutasa R, et al
    Trends in the incidence of cancers of the breast and female genital tract in Harare, Zimbabwe 1990-2019.
    Int J Cancer. 2026;159:844-852.
    >> Share


    Int J Oncol

  76. SINGH T, Katiyar SK
    [Retracted] Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase?2.
    Int J Oncol. 2026;69:91.
    >> Share


    Int J Radiat Oncol Biol Phys

  77. DIONISI F, Sanguineti G
    The Infinite Choices of Local (Re)-Treatment for Oligometastatic Breast Cancer: Angst, Leap of Faith, or a Safe Bet?
    Int J Radiat Oncol Biol Phys. 2026;125:991-992.
    >> Share

  78. MEYER J, Zoberi JE, Kim H, Tran A, et al
    A National Survey of Medical Physicists: Part 1-Practice Patterns for High-Dose-Rate Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2026;125:1228-1240.
    >> Share

  79. SPIEGEL DY, Levey J, Keko M, Modest A, et al
    Radiation Dose and Lymphedema Risk After Immediate Lymphatic Reconstruction and Axillary Lymph Node Dissection.
    Int J Radiat Oncol Biol Phys. 2026;125:1071-1080.
    >> Share

  80. MILGROM SA, Paganetti H, Dama H, Renfro L, et al
    Subsequent Neoplasm Risk after Modern Mediastinal Radiotherapy for Pediatric Hodgkin Lymphoma: Insights from a Multi-Institutional Children's Oncology Group Trial.
    Int J Radiat Oncol Biol Phys. 2026 Feb 6:S0360-3016(26)00361.
    >> Share

  81. SOURIAL F, Champ C, Beriwal S
    The Critical Role of Dose Homogeneity in Modern Breast Hypofractionation.
    Int J Radiat Oncol Biol Phys. 2026;125:1059-1070.
    >> Share


    J Natl Cancer Inst

  82. CASTRO-ESPIN C, His M, Fournier A, Biessy C, et al
    Pre-diagnosis thyroid biomarkers and breast cancer survival: evidence from a European prospective cohort study.
    J Natl Cancer Inst. 2026 Jun 25:djag195. doi: 10.1093.
    >> Share

  83. ARASU VA, Gadgil T, Rothstein JH, Alexeeff SE, et al
    Comparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research Bank.
    J Natl Cancer Inst. 2026 Jun 23:djag154. doi: 10.1093.
    >> Share


    J Nucl Med

  84. KUPER AT, Shiyam Sundar LK, Djaileb L, Roschlak J, et al
    SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [(68)Ga]Ga-DOTATOC and [(68)Ga]Ga-SSO120 with [(18)F]FDG PET.
    J Nucl Med. 2026 Jun 25:jnumed.126.272521. doi: 10.2967/jnumed.126.272521.
    >> Share


    Mol Ther Oncol

  85. CHOUDHURY PR, Chakravarti M, Bera S, Arora P, et al
    Atorvastatin pre-exposure in hypercholesterolemia remedies 27HC mediated dendritic cell dysfunctions in triple-negative breast cancer.
    Mol Ther Oncol. 2026;34:201250.
    >> Share


    NPJ Breast Cancer

  86. CHOI JE, Yan Q, Wang J, Salgia NJ, et al
    The suppressive function of ILC2 cells is regulated by beta2-adrenergic receptor signaling in breast cancer.
    NPJ Breast Cancer. 2026 Jun 20. doi: 10.1038/s41523-026-00990.
    >> Share

  87. BODELON C, Amgad M, Hodge JM, Elsebaie MAT, et al
    Effects of breast cancer risk factors on the tumor microenvironment: a morphological deep-learning analysis of three prospective cohorts.
    NPJ Breast Cancer. 2026 Jun 22. doi: 10.1038/s41523-026-00994.
    >> Share

  88. CHEN Y, Liu B, Chen Z, Huang P, et al
    Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4/6 inhibitor progression.
    NPJ Breast Cancer. 2026 Jun 24. doi: 10.1038/s41523-026-00982.
    >> Share

  89. SHAO L, Zhang M, Zhang L, Sun F, et al
    Multimodal imaging and artificial intelligence for response assessment to neoadjuvant therapy in breast cancer: a comprehensive review.
    NPJ Breast Cancer. 2026 Jun 24. doi: 10.1038/s41523-026-00995.
    >> Share

  90. ABOU ZEIDANE R, Hauk B, Lichtman-Mikol S, Pisano C, et al
    Prognostic consistency of oncotype DX(R) molecular assay across racial groups in early-stage hormone receptor-positive breast cancer.
    NPJ Breast Cancer. 2026 Jun 25. doi: 10.1038/s41523-026-00996.
    >> Share

  91. WIDSCHWENDTER M, Schmutzler R, Pashayan N, Wesseling J, et al
    Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.
    NPJ Breast Cancer. 2026 Jun 25. doi: 10.1038/s41523-026-00998.
    >> Share

  92. SHIMOI T, Shibata N, Kitada M, Tsuneizumi M, et al
    Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE.
    NPJ Breast Cancer. 2026 Jun 26. doi: 10.1038/s41523-026-00997.
    >> Share


    PLoS One

  93. KHAN MM, Hossain MA, Zohora F, Sohel M, et al
    In silico screening and molecular analyses identify apigenin from Scutellaria barbata as a potent AKT1 inhibitor in breast cancer.
    PLoS One. 2026;21:e0338874.
    >> Share

  94. PHETDEE C, Naephrai S, Pradain M, Panporm Y, et al
    Synergistic anticancer activity of antimicrobial peptide nisin and doxorubicin against breast cancer cells via modulation of membrane permeability.
    PLoS One. 2026;21:e0352312.
    >> Share


  95. Retraction: Biogenic green synthesis of MgO nanoparticles using Saussurea costus biomasses for a comprehensive detection of their antimicrobial, cytotoxicity against MCF-7 breast cancer cells and photocatalysis potentials.
    PLoS One. 2026;21:e0351977.
    >> Share


    Proc Natl Acad Sci U S A

  96. BU W, Lee TD, Anurag M, Dou Y, et al
    Rat somatic genome editing enables ER+ breast cancer modeling.
    Proc Natl Acad Sci U S A. 2026;123:e2529653123.
    >> Share


    Radiol Artif Intell

  97. HAN L, Tan T, Zhang T, Gao Y, et al
    Tumor-preserving Deformable Registration of Longitudinal Breast DCE MRI during Neoadjuvant Chemotherapy.
    Radiol Artif Intell. 2026 May 20:e250789. doi: 10.1148/ryai.250789.
    >> Share


    Radiology

  98. LEHMAN CD, Mercaldo SF, Azam S, Tamimi RM, et al
    Longitudinal Analysis of Changes in Deep Learning Image-based Breast Cancer Risk Scores over Time.
    Radiology. 2026;319:e253023.
    >> Share

  99. MANN RM, Wang X
    Beyond Static Prediction: Tracking AI Breast Cancer Risk over Time.
    Radiology. 2026;319:e261198.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016